PharmiWeb

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary ...

Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.CULVER CITY, ...
MarketWatch

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA(R) in BCG-Unresponsive Papillary Bladder Cancer

The MarketWatch News Department was not involved in the creation of this content. -- Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for ...
Morningstar

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company’s supplemental ...